Literature DB >> 15140029

A novel polymorphic GATA site in the human IL-12Rbeta2 promoter region affects transcriptional activity.

J G I van Rietschoten1, R Westland, R van den Bogaard, M A Nieste-Otter, A van Veen, R E Jonkers, T C T M van der Pouw Kraan, M T den Hartog, E A Wierenga.   

Abstract

Interleukin-12 (IL-12) is a potent inducer of interferon-gamma production by T cells and is a major factor for the development of T-helper 1 (Th1) cells. It exerts its biological effects through binding to the IL-12 receptor (IL-12R), a heterodimer composed of a 1 and a beta2 subunits. The signaling beta2 chain is expressed on Th1 cells and to a lesser extent on Th0 cells, but not on Th2 cells, rendering these latter cells unresponsive to IL-12. Polymorphisms in the coding region of the IL-12Rbeta2 gene were shown to be associated with atopic disease. Here, we analyzed the 5'-regulatory region of the human IL-12Rbeta2 gene by denaturing high-performance liquid chromatography (Transgenomic WAVE system, San Jose, CA). We found five novel single-nucleotide polymorphisms (SNPs) in the proximal 1.2 kb IL-12Rbeta2 promoter region, i.e. -237C/T, -465A/G, -1023A/G, -1033T/C, and -1035A/G. SNP -465A/G is of particular interest as it determines the integrity of a GATA consensus site. By functional comparison of both -465 alleles in transient transfection assays, we show that promoter activity is increased in case of the -465G allele, disrupting the intact GATA site. Comparison of the prevalence of -465A/G SNP alleles in small cohorts of allergic asthmatic and healthy control individuals provided no evidence for an altered distribution in the asthmatic population. In conclusion, we have identified a novel polymorphic GATA site that may affect transciptional activity of the human IL-12Rbeta2 gene under GATA3-mediated, Th2-polarizing conditions. Copyright 2004 Blackwell Munksgaard

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15140029     DOI: 10.1111/j.0001-2815.2004.00223.x

Source DB:  PubMed          Journal:  Tissue Antigens        ISSN: 0001-2815


  6 in total

1.  Role of neuronal interferon-gamma in the development of myelopathy in rats infected with human T-cell leukemia virus type 1.

Authors:  Yukiko Miyatake; Hitoshi Ikeda; Akihiro Ishizu; Tomohisa Baba; Toru Ichihashi; Akira Suzuki; Utano Tomaru; Masanori Kasahara; Takashi Yoshiki
Journal:  Am J Pathol       Date:  2006-07       Impact factor: 4.307

2.  pri-miR-34b/c rs4938723 polymorphism is associated with hepatocellular carcinoma risk: a case-control study in a Chinese population.

Authors:  Chun-Jia Liu; Xue-Wei Ma; Xue-Jun Zhang; Shi-Qiang Shen
Journal:  Int J Mol Epidemiol Genet       Date:  2017-02-15

3.  Polymorphism of the 5' flanking region of the IL-12 receptor beta2 gene partially determines the clinical types of leprosy through impaired transcriptional activity.

Authors:  H Ohyama; K Ogata; K Takeuchi; M Namisato; Y Fukutomi; F Nishimura; H Naruishi; T Ohira; K Hashimoto; T Liu; M Suzuki; Y Uemura; S Matsushita
Journal:  J Clin Pathol       Date:  2005-07       Impact factor: 3.411

4.  Analysis of eight genes modulating interferon gamma and human genetic susceptibility to tuberculosis: a case-control association study.

Authors:  Marlo Möller; Almut Nebel; Paul D van Helden; Stefan Schreiber; Eileen G Hoal
Journal:  BMC Infect Dis       Date:  2010-06-07       Impact factor: 3.090

5.  Functional analysis of differences in transcriptional activity conferred by genetic variants in the 5' flanking region of the IL12RB2 gene.

Authors:  Nahoko Kato-Kogoe; Hideki Ohyama; Soichiro Okano; Koji Yamanegi; Naoko Yamada; Masaki Hata; Hiroshi Nishiura; Yoshimitsu Abiko; Nobuyuki Terada; Keiji Nakasho
Journal:  Immunogenetics       Date:  2015-11-09       Impact factor: 2.846

6.  Prevalence, distribution and functional significance of the -237C to T polymorphism in the IL-12Rβ2 promoter in Indian tuberculosis patients.

Authors:  Vikas Kumar Verma; Vibha Taneja; Anand Jaiswal; Sangeeta Sharma; Digamber Behera; Vishnubhatla Sreenivas; Shyam Singh Chauhan; Hanumanthappa Krishna Prasad
Journal:  PLoS One       Date:  2012-04-03       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.